ADIA Adia Med, Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1160420 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin35.3%
Operating margin-38.0%
Net margin-41.5%
FCF margin-27.2%
EBITDA margin-37.5%
Returns
ROE-111.0%
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets60.4%
Debt / equity0.00x
Current ratio1.09x
Interest coverage-20.10x
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio—
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $454,385 | $388,585 | $176,275 | $178,550 | $332,048 | $118,146 | $71,764 |
| Cost of revenue | $233,404 | $202,805 | $108,698 | $230,341 | $128,563 | $92,223 | $57,712 |
| Gross profit | $220,981 | $185,780 | $67,577 | -$51,791 | $203,485 | $25,923 | $14,052 |
| R&D expense | $4,375 | $0 | — | -$1,664 | $6,192 | $24,616 | — |
| SG&A expense | $243,731 | $208,315 | $182,490 | $143,544 | $100,491 | $132,846 | $103,074 |
| Operating income | -$39,150 | -$44,971 | -$151,920 | -$218,563 | $79,200 | -$116,587 | -$110,544 |
| Interest expense | $13,990 | -$11,786 | $10,980 | $9,437 | $9,074 | $7,410 | $5,675 |
| Pretax income | -$53,015 | -$56,382 | -$162,525 | -$225,625 | $70,376 | -$123,997 | -$116,219 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$53,015 | -$56,382 | -$162,525 | -$225,625 | $70,376 | -$123,997 | -$116,219 |
| EBITDA | -$37,503 | -$43,528 | -$150,669 | -$217,599 | $80,462 | -$115,444 | -$109,770 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 94.40M | 161.40M | 94.40M | — | 158.17M | 89.64M | 95.90M |
| Balance sheet | |||||||
| Cash & equivalents | $1.14M | $128,115 | $136,716 | $79,392 | $154,002 | $115,099 | $37,463 |
| Receivables | $53,360 | $44,010 | $79,360 | $33,360 | — | — | — |
| Inventory | $348,500 | — | — | $25,025 | — | — | — |
| Current assets | $1.56M | $342,598 | $358,907 | $161,510 | — | — | — |
| PP&E, net | $41,790 | $33,495 | $34,938 | $30,695 | — | — | — |
| Intangibles | — | — | — | $0 | — | — | — |
| Total assets | $2.45M | $744,054 | $776,868 | $594,826 | — | — | — |
| Current liabilities | $1.44M | $1.06M | $1.11M | $745,195 | — | — | — |
| Total liabilities | $1.48M | $1.12M | $1.20M | $852,500 | — | — | — |
| Shareholders' equity | $970,404 | -$476,581 | -$420,199 | -$257,674 | -$74,301 | -$144,676 | -$90,679 |
| Cash flow statement | |||||||
| Operating cash flow | -$75,575 | -$109,041 | -$55,037 | -$70,707 | $59,020 | -$136,366 | -$31,175 |
| Capital expenditure | $9,941 | $1 | $5,494 | $1 | $0 | $13,199 | $0 |
| Free cash flow | -$85,516 | -$109,042 | -$60,531 | -$70,708 | $59,020 | -$149,565 | -$31,175 |
| Investing cash flow | -$9,941 | -$5,301 | -$5,494 | $537 | -$15,785 | -$14,009 | -$2,794 |
| Financing cash flow | $1.10M | $105,741 | $117,855 | -$4,440 | -$4,332 | $228,011 | $65,109 |
| Depreciation & amortization | $1,647 | $1,443 | $1,251 | $964 | $1,262 | $1,143 | $774 |
| Stock-based compensation | $0 | $0 | $0 | $42,250 | $0 | $0 | $0 |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.